期刊文献+

血脂康对慢性心力衰竭患者心功能、高敏C反应蛋白及血脂的影响 被引量:2

Effect of Xuezhikang on heart function,hs-CRP and blood liquid in patients with chronic heart failure
暂未订购
导出
摘要 目的探讨血脂康对慢性心力衰竭(CHF)患者的心功能(左室射血分数)、高敏C反应蛋白(hs-CRP)及血脂的影响。方法将65例CHF患者随机分为2组,均予常规治疗,治疗组在此基础上予血脂康口服,治疗前及治疗后1周、2周、4周抽血查血脂及hs-CRP,查心脏彩超等。结果2组治疗后血脂无明显变化,而治疗组治疗1周后hs-CRP即开始降低,心功能开始改善,与治疗前及对照组比较均有显著性差异(P均<0.05)。结论血脂康在早期即可明显降低慢性心力衰竭患者hs-CRP的水平,改善心功能,与血脂TC、LDL-C下降无相关性,说明血脂康治疗心力衰竭是通过调脂以外起作用的,可能对心力衰竭患者的治疗带来益处。 Objective It is to explore the effect of Xuezhikang on heart function, hs- CRP and blood liquid in patients with chronic heart failure (CHF). Methods 65 patients with CHF were randomly divided into 2 groups and both were treated with normal drugs. The treatment group was given Xuezhikang by oral use on the basis of treatment above. Blood was gotten before treatment and 1,2,4 weeks' after treatment to determine blood liquid and hs- CRP, hearts in the patients were also examined by color ultrasound. Results There was no obvious change of blood liquid after treatment in both groups, but hs- CRP in treatment group began to decrease and the heart function began to be improved after one week's treatment. Compared with that before treatment and in control group, the differences were significant (P 〈 0.05). Conclusion Xuezhikang can low down the level of hs - CRP and improve heart function in the early time in patients with CHF, but the function is not related with blood liquid (TC, LDL- C) decrease. It shows that Xuezhikang has some function on CHF not by improving liquid, so it can bring some benefit for the treatment for CHF.
作者 刘喆
出处 《现代中西医结合杂志》 CAS 2009年第10期1093-1094,共2页 Modern Journal of Integrated Traditional Chinese and Western Medicine
关键词 血脂康 慢性心力衰竭 高敏C反应蛋白 血脂 Xuezhikang chronic heart failure hs-CRP blood liquid
  • 相关文献

参考文献9

  • 1Kjekshus J, Pedersen TR, OlssonAG, et al. The effects of simvasrain on the incidence of heart failure in patients with coronary heart disease[J]. J Card Fail, 1997,3(4) :249 - 254
  • 2Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastain on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range[ J ]. Ann Intern Med, 1998, 129(9) :681 - 689
  • 3Ferrari R, Bachetti T, Confortini R, et al. Tumor necrosis factor sotube receptors in patients with various degrees of confestive failure [J]. Circulation,1995,92:1479- 1486
  • 4Porter KE, Turner NA, OReagn D J, et at. Sinvastain reduces human atrial myofibroblast proliferation indepently of cholesterol lowering via inhibition of rhoA[J]. Cardiovasc Res,2004,61(4) :745 - 755
  • 5Torre-Amione G, Kapadia S, Benedict C, et al. Proinflammatory cytokine levels in patients with depressed left ventricular injection fravtion. A receptor from the Studies of left Ventricular Dysfunction(SOLVD) [J ]. J Am Coll Cardia, 1996,27 : 1201 - 1206
  • 6Ankrast P, Yndestad A, DamasJK, et al. Inflammation and chronic heart failure potential the rapeutic role of intravenous immunoglobulin[ J ]. Autoimmun Rev, 2004 ( 3 ) : 221 - 227
  • 7Sola S,Mir MQ,Rajagopalan S, er al. Statin therapy is associated with improved cardiovascular outcomes and levels of inflammatory markers in patients with heart failure[J]. J Card Fail, 2005, 11 (8) :607
  • 8杨艳华,王林.他汀类药物多效性及在心力衰竭中的应用[J].中国心血管杂志,2007,12(4):314-315. 被引量:13
  • 9刘尊齐,崔连群,王勇,孔庆赞,刘继东,李峰,盖玉生,赵传艳.大剂量血脂康在经皮冠状动脉介入术中的炎症抑制作用[J].中国病理生理杂志,2007,23(9):1703-1705. 被引量:11

二级参考文献16

  • 1汤圣兴,祁述善,周胜华,徐浩,王安才.阿托伐他汀对自发性高血压大鼠心室重塑的作用及机制[J].中国病理生理杂志,2006,22(8):1535-1539. 被引量:11
  • 2第一届全国内科学术会议心血管病组.关于冠状动脉性心脏病命名及诊断标准的建议[J].中华心血管病杂志,1981,9(1):75-76.
  • 3Liao JK, Laufs U. Pleiotropic effects of statins[J]. Annu Rev Pharmacol Toxicol, 2005,45 : 89-118.
  • 4Nakata S, Tsutsui M, Shimokawa H, et al. Statin treatment upregulates vascular neuronal nitric oxide synthase through Akt/NF-kappaB pathway[J]. Arterioscler Thromh Vasc Biol, 2007,27:92-98.
  • 5PouratiI, Kimmelstiel C, Rand W, et al. Statin use is associated with enhanced collateralization of severely diseased coronary arteries[J]. Am Heart J, 2003,146 : 876-878.
  • 6Dichtl W, Dulak J, Frick M, et al. HMG-CoA reductase inhibition regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells[J]. Arterioscler Thromb Vase Biol, 2003,23 : 58-63.
  • 7Watanabe T, Yasunari K, Nakamura M. Antioxidative actions of statins., potential mechanisms for antiathersclerotic effects[J]. Mini Rev Med Chem, 2006,6 : 505-508.
  • 8Pliquett RU, Cornish KG, Peuler JD, et al. Simvastatin normalizes autonomic neural control in experimental heart failure[J]. Circulation,2003,107 : 2493-2498.
  • 9Mozaffarian D, Nye R, Levy WC. Statin therapy is associated with lower mortality among patients with severe heart failure [J]. Am J Cardiol,2004,93:1124-1129.
  • 10Ray JG,Gong Y, Sykora K, et al. Statin use and survival outcomes in elderly patients with heart failure[J]. Arch Intern Med, 2005,165 : 62-67.

共引文献21

同被引文献30

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部